TMPRSS6

Transmembrane protease serine 6 · Q8IU80 · TMPRSS6 on Sugi Atlas →

8,806 patent compounds predicted against TMPRSS6, 4,412 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Trifluoroacetic Acid (SCHEMBL3910393)	0.55	10/20
Trifluoroacetic Acid (SCHEMBL3907682)	0.52	10/20
Trifluoroacetic Acid (SCHEMBL3899650)	0.59	9/20
Trifluoroacetic Acid (SCHEMBL3464974)	0.41	9/20
Trifluoroacetic Acid (SCHEMBL3898272)	0.56	8/20
Trifluoroacetic Acid (SCHEMBL2538019)	0.45	8/20
Trifluoroacetic Acid (SCHEMBL3912340)	0.42	8/20
Trifluoroacetic Acid (SCHEMBL3899556)	0.64	7/20
Trifluoroacetic Acid (SCHEMBL3898961)	0.63	7/20
Trifluoroacetic Acid (SCHEMBL3909981)	0.44	7/20
SCHEMBL4372182	0.51	6/20
Trifluoroacetic Acid (SCHEMBL3899718)	0.46	6/20
Trifluoroacetic Acid (SCHEMBL3905613)	0.46	6/20
SCHEMBL1328105	0.45	6/20
Trifluoroacetic Acid (SCHEMBL3898518)	0.53	5/20
SCHEMBL3910394	0.51	5/20
Trifluoroacetic Acid (SCHEMBL842110)	0.49	5/20
Trifluoroacetic Acid (SCHEMBL3900547)	0.43	5/20
Trifluoroacetic Acid (SCHEMBL3901693)	0.38	5/20
SCHEMBL3826791	0.54	4/20

Clinical trials — most relevant to TMPRSS6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical Role of Testosterone and Dihydrotestosterone and Which of Them Should be Inhibited in COVID-19 Patients - A Double-edged Sword?	PHASE4	UNKNOWN
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)	PHASE3	UNKNOWN
Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19	PHASE2/PHASE3	UNKNOWN
Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit	PHASE3	WITHDRAWN
Proxalutamide Treatment for COVID-19 Female Outpatients	PHASE3	WITHDRAWN
Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus	PHASE2	UNKNOWN
NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia	PHASE2	COMPLETED
Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer	PHASE2	COMPLETED
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer	PHASE2	COMPLETED
Nebulised BromAc in Healthy Volunteers	PHASE1	COMPLETED
Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications	PHASE1	UNKNOWN
Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)	EARLY_PHASE1	UNKNOWN
Genes-in-Action - Hepcidin Regulation of Iron Supplementation	nan	COMPLETED
Osteopathic Manipulative Therapy Effects on Post-Acute Sequelae of COVID-19 (PASC) or Long COVID	nan	RECRUITING
Nasal Epithelial Genetic and Single Cell RNA COVID-19 Study	nan	WITHDRAWN
PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort	nan	UNKNOWN
Cardiac Injury in COVID-19: a Pathology Study	nan	UNKNOWN
Seawater Nasal Wash to Relieve COVID-19 Nasal Symptoms and Reduce SARS-CoV-2 Viral Load.	nan	COMPLETED
In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity	nan	WITHDRAWN
Angiotensin-converting Enzyme 2 (ACE2) Expression in Tonsils and Adenoids	nan	WITHDRAWN
MIcrovascular Dysfunction in CRitically Ill cOVID-19 Patients	nan	UNKNOWN
Impact of the Genetic Polymorphism on COVID-19 in Egypt	nan	UNKNOWN
ACE2 Gender Differences in Stroke With COVID-19	nan	COMPLETED
ERG Protein Expression in Prostatic Adenocarcinoma and Its Clinicopathological Features	nan	UNKNOWN
COVID-19 Blood Pressure Endothelium Interaction Study (OBELIX)	nan	COMPLETED
Periodontal Health in Post COVID-19 Patients	nan	UNKNOWN
Anti-Androgen Treatment for COVID-19	nan	COMPLETED
COVID-19 Infection and Fetal-neonatal Outcomes	nan	UNKNOWN
Association Between Periodontitis and Coronavirus Disease (COVID-19)	nan	COMPLETED
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TMPRSS6 binder may also engage these)

Protein	Name	Similarity
Q9DBI0	—	0.998	Q9DBI0 →
D3ZTE0	—	0.997	D3ZTE0 →
Q80YC5	—	0.994	Q80YC5 →
Q6IE64	—	0.994	Q6IE64 →
Q3UZ09	—	0.993	Q3UZ09 →
P22891	—	0.992	P22891 →
F7	Coagulation factor VII	0.992	landscape →
Q2F9P2	—	0.991	Q2F9P2 →
Q9R098	—	0.990	Q9R098 →
Q9GLP2	—	0.990	Q9GLP2 →
ST14	Suppressor of tumorigenicity 14 protein	0.990	landscape →
Q9NZP8	—	0.989	Q9NZP8 →
Q7M761	—	0.989	Q7M761 →
Q7RTY7	—	0.989	Q7RTY7 →
P00745	—	0.989	P00745 →
Q04962	—	0.989	Q04962 →
Q8K480	—	0.989	Q8K480 →
P56677	—	0.989	P56677 →
PROC	Vitamin K-dependent protein C	0.989	landscape →
P98140	—	0.989	P98140 →
Q9CQW3	—	0.988	Q9CQW3 →
Q70UZ7	—	0.988	Q70UZ7 →
Q2F9P4	—	0.988	Q2F9P4 →
Q9BY79	—	0.988	Q9BY79 →
Q7TN88	—	0.988	Q7TN88 →
O97507	—	0.987	O97507 →
Q0IIH7	—	0.987	Q0IIH7 →
P31394	—	0.987	P31394 →
Q05511	—	0.987	Q05511 →
Q8BIK6	—	0.987	Q8BIK6 →